Zanubrutinib (Brukinsa®) – Waldenström's disease, first-line (chemo-immunotherapy unsuitable) or after at least 1 previous therapy

Characteristics

Start date 15.12.2021
Resolution 16.06.2022
INN Zanubrutinib
Brand name Brukinsa®
Pharm. company Dossier: BeiGene Germany GmbH
New distributor: BeiGene Netherlands B.V.
G-BA procedure ID 2021-12-15-D-761
ATC code L01EL03
Therapeutic area Oncological diseases
Reason for procedure Initial assessment

Indication (German)

BRUKINSA monotherapy is used to treat adult patients with Morbus Waldenström (MW) who have received at least one prior therapy, or for first-line therapy in patients who are not suitable for chemo-immunotherapy.

Subpopulation Indication Comparator
Adults with Morbus Waldenström (MW) who have received at least one prior therapy or adults without prior therapy who are not suitable for chemoimmunotherapy A patient-specific therapy taking into account the general condition and, if applicable, previous therapies and the duration of remission after initial therapy.

9. Associated procedures



<< List of all resolutions